Heptares Therapeutics Ltd.:製品開発パイプライン動向2015

◆英語タイトル:Heptares Therapeutics Ltd. - Product Pipeline Review - 2015
◆商品コード:GMDHC06874CDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年3月31日
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥168,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥504,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Heptares Therapeutics Ltd. – Product Pipeline Review – 2015

Summary

Global Markets Direct’s, ‘Heptares Therapeutics Ltd. – Product Pipeline Review – 2015’, provides an overview of the Heptares Therapeutics Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Heptares Therapeutics Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Heptares Therapeutics Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Heptares Therapeutics Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Heptares Therapeutics Ltd.’s pipeline products

Reasons to buy

- Evaluate Heptares Therapeutics Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Heptares Therapeutics Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Heptares Therapeutics Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Heptares Therapeutics Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Heptares Therapeutics Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Heptares Therapeutics Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Heptares Therapeutics Ltd. Snapshot 6
Heptares Therapeutics Ltd. Overview 6
Key Information 6
Key Facts 6
Heptares Therapeutics Ltd. – Research and Development Overview 7
Key Therapeutic Areas 7
Heptares Therapeutics Ltd. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products – Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Heptares Therapeutics Ltd. – Pipeline Products Glance 16
Heptares Therapeutics Ltd. – Clinical Stage Pipeline Products 16
Phase I Products/Combination Treatment Modalities 16
Heptares Therapeutics Ltd. – Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Heptares Therapeutics Ltd. – Drug Profiles 19
HTL-9936 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Drug to Agonize Muscarinic M4 Receptors for Psychosis 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
HTL-14242 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule to Agonize GPR-39 for Type 2 Diabetes 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule to Antagonize CGRP for Migraine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody to Target GPCR for Pain, Metabolic Disorders and Inflammation 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule to Antagonize Orexin 1/2 for Insomnia 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule to Target Chemokine (C-X-C Motif) Receptor 4 for Cancer and HIV 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecule to Target GPCR for CNS Disorders 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecule to Target mGluR2 for Schizophrenia 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Target GPCR 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Target GPCRs for Pain, Metabolic Disorders and Inflammation 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Heptares Therapeutics Ltd. – Pipeline Analysis 35
Heptares Therapeutics Ltd. – Pipeline Products by Target 35
Heptares Therapeutics Ltd. – Pipeline Products by Route of Administration 36
Heptares Therapeutics Ltd. – Pipeline Products by Molecule Type 37
Heptares Therapeutics Ltd. – Pipeline Products by Mechanism of Action 38
Heptares Therapeutics Ltd. – Recent Pipeline Updates 39
Heptares Therapeutics Ltd. – Locations And Subsidiaries 42
Head Office 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

[List of Tables]
Heptares Therapeutics Ltd., Key Information 6
Heptares Therapeutics Ltd., Key Facts 6
Heptares Therapeutics Ltd. - Pipeline by Indication, 2015 9
Heptares Therapeutics Ltd. - Pipeline by Stage of Development, 2015 10
Heptares Therapeutics Ltd. - Monotherapy Products in Pipeline, 2015 11
Heptares Therapeutics Ltd. - Partnered Products in Pipeline, 2015 12
Heptares Therapeutics Ltd. - Partnered Products/ Combination Treatment Modalities, 2015 13
Heptares Therapeutics Ltd. - Out-Licensed Products in Pipeline, 2015 14
Heptares Therapeutics Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015 15
Heptares Therapeutics Ltd. - Phase I, 2015 16
Heptares Therapeutics Ltd. - Preclinical, 2015 17
Heptares Therapeutics Ltd. - Discovery, 2015 18
Heptares Therapeutics Ltd. - Pipeline by Target, 2015 35
Heptares Therapeutics Ltd. - Pipeline by Route of Administration, 2015 36
Heptares Therapeutics Ltd. - Pipeline by Molecule Type, 2015 37
Heptares Therapeutics Ltd. - Pipeline Products by Mechanism of Action, 2015 38
Heptares Therapeutics Ltd. - Recent Pipeline Updates, 2015 39

[List of Figures]
Heptares Therapeutics Ltd. - Pipeline by Top 10 Indication, 2015 8
Heptares Therapeutics Ltd. - Pipeline by Stage of Development, 2015 10
Heptares Therapeutics Ltd. - Monotherapy Products in Pipeline, 2015 11
Heptares Therapeutics Ltd. - Out-Licensed Products in Pipeline, 2015 14
Heptares Therapeutics Ltd. - Pipeline by Top 10 Target, 2015 35
Heptares Therapeutics Ltd. - Pipeline by Top 10 Route of Administration, 2015 36
Heptares Therapeutics Ltd. - Pipeline by Top 10 Molecule Type, 2015 37
Heptares Therapeutics Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 38

【レポートのキーワード】

Heptares Therapeutics Ltd.、製品開発、製薬、医薬品、治験、研究開発、パイプライン

★調査レポート[Heptares Therapeutics Ltd.:製品開発パイプライン動向2015] (コード:GMDHC06874CDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[Heptares Therapeutics Ltd.:製品開発パイプライン動向2015]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆